Treatment of cutaneous lymphoma with etretinate
Authors:
- 1 July 1983
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 109 (1) , 49-56
Abstract
Twelve patients with various types of lymphoma were treated with etretinate. The diagnosis included parapsoriasis en plaque, epidermotropic lymphoma (diffuse chronic erythroderma with atypical mononuclear cells, Sézary syndrome or MF tumours) and non-epidermotropic lymphoma. The patients received etretinate in a dose of 0.8 to 1.0 mg/kg/day for 2 to 14 months. No additional therapy was given. Patients with epidermotropic lymphomas stage I and II had a favourable clinical and histological response whereas those with deeply infiltrating tumours remained unresponsive. Patients with parapsoriasis en plaque and poikiloderma showed little response. Of the four patients who discontinued the treatment, three had recurrences after 3 to 4 months but one remained clear. The results obtained with etretinate may equal those obtained with more aggressive treatments.Keywords
This publication has 7 references indexed in Scilit:
- Treatment of cutaneous T-cell lymphoma with a new aromatic retinoid (Ro 10-9359)Archives of Dermatological Research, 1982
- PUVA treatment of erythrodermic and plaque type mycosis fungoidesJournal of the American Academy of Dermatology, 1981
- Retinoids, cancer, and the skinArchives of Dermatology, 1981
- Evaluation and Treatment of Mycosis Fungoides LymphomaInternational Journal of Dermatology, 1980
- Cutaneous T cell lymphoma: Mycosis fungoides, Sézary syndrome, and other variantsJournal of the American Academy of Dermatology, 1980
- Lymphocyte Traffic, T-Cell Malignancies and the SkinJournal of Investigative Dermatology, 1978
- Therapeutic effects of an aromatic retinoic acid analog on chemically induced skin papillomas and carcinomas of miceEuropean Journal of Cancer (1965), 1974